These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24503579)

  • 1. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.
    De Filette M; Soehle S; Ulbert S; Richner J; Diamond MS; Sinigaglia A; Barzon L; Roels S; Lisziewicz J; Lorincz O; Sanders NN
    PLoS One; 2014; 9(2):e87837. PubMed ID: 24503579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
    Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
    Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.
    Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L
    Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
    Chu JH; Chiang CC; Ng ML
    J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
    Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
    Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.
    Shrestha B; Ng T; Chu HJ; Noll M; Diamond MS
    Vaccine; 2008 Apr; 26(16):2020-33. PubMed ID: 18339459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.
    Chaintoutis SC; Diakakis N; Papanastassopoulou M; Banos G; Dovas CI
    Clin Vaccine Immunol; 2015 Sep; 22(9):1040-9. PubMed ID: 26178384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.
    Spohn G; Jennings GT; Martina BE; Keller I; Beck M; Pumpens P; Osterhaus AD; Bachmann MF
    Virol J; 2010 Jul; 7():146. PubMed ID: 20604940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus.
    Verstrepen BE; Oostermeijer H; Fagrouch Z; van Heteren M; Niphuis H; Haaksma T; Kondova I; Bogers WM; de Filette M; Sanders N; Stertman L; Magnusson S; Lőrincz O; Lisziewicz J; Barzon L; Palù G; Diamond MS; Chabierski S; Ulbert S; Verschoor EJ
    PLoS One; 2014; 9(11):e112568. PubMed ID: 25392925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
    McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
    J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
    Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K
    Virol J; 2015 Apr; 12():54. PubMed ID: 25889682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection with non-lethal West Nile virus Eg101 strain induces immunity that protects mice against the lethal West Nile virus NY99 strain.
    Kumar M; O'Connell M; Namekar M; Nerurkar VR
    Viruses; 2014 Jun; 6(6):2328-39. PubMed ID: 24915459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
    Bonafé N; Rininger JA; Chubet RG; Foellmer HG; Fader S; Anderson JF; Bushmich SL; Anthony K; Ledizet M; Fikrig E; Koski RA; Kaplan P
    Vaccine; 2009 Jan; 27(2):213-22. PubMed ID: 18996430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01.
    Iyer AV; Pahar B; Boudreaux MJ; Wakamatsu N; Roy AF; Chouljenko VN; Baghian A; Apetrei C; Marx PA; Kousoulas KG
    Vaccine; 2009 Feb; 27(6):893-903. PubMed ID: 19070640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.
    Martina BE; Koraka P; van den Doel P; van Amerongen G; Rimmelzwaan GF; Osterhaus AD
    Vaccine; 2008 Jan; 26(2):153-7. PubMed ID: 18069096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
    El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE).
    Escribano-Romero E; Gamino V; Merino-Ramos T; Blázquez AB; Martín-Acebes MA; de Oya NJ; Gutiérrez-Guzmán AV; Escribano JM; Höfle U; Saiz JC
    Vaccine; 2013 Sep; 31(41):4523-7. PubMed ID: 23933372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
    Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
    Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.
    Schepp-Berglind J; Luo M; Wang D; Wicker JA; Raja NU; Hoel BD; Holman DH; Barrett AD; Dong JY
    Clin Vaccine Immunol; 2007 Sep; 14(9):1117-26. PubMed ID: 17634508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.